Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MedChew with dronabinol
- Development stage
- Unknown
- Lead developer
- Axim Biotechnologies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MedChew with dronabinol is a patented controlled-release chewing gum delivery system containing dronabinol, a synthetic form of tetrahydrocannabinol (THC). Developed by Axim Biotechnologies, it is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with cancer or AIDS. Dronabinol acts as an agonist at cannabinoid receptors CB1 and CB2. The chewing gum formulation is designed to bypass first-pass metabolism in the liver by allowing for mucosal absorption, which aims to improve bioavailability and reduce side effects compared to traditional oral capsule formulations like Marinol.
- Brand names
- MedChew
- Other names
- dronabinol chewing gumMedChew Dronabinol
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on MedChew with dronabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedChew with dronabinol.